2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
70
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Gemcitabine
157
Cisplatin
117
pembrolizumab
81
Cystectomy
46
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Docetaxel
39
atezolizumab
33
Magnetic Resonance Spectroscopy
33
Radiotherapy
31
durvalumab
30
avelumab
26
BCG Vaccine
26
Specimen Handling
25
Cystoscopy
24
enfortumab vedotin
23
Doxorubicin
23
Fluorouracil
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Ipilimumab
14
Filgrastim
14
5-aminolevulinic acid hexyl ester
14
Transurethral Resection of Bladder
13
Surgical Procedures, Operative
13
Sunitinib
13
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-05-01
DP-04
AstraZeneca
Recruiting
100 enrolled